Lancet, The

Volume 396, Issue 10259

Reimagining long-term care

SARS-CoV-2 antibody seroprevalence in patients receiving dialysis in the USA

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

Building a tuberculosis-free world while responding to the COVID-19 pandemic

 

Annals of Medicine and Surgery

Volume 59

Corneal parameters 18 Months following collagen cross-linkage treatment (CXL) for keratoconus in western Saudi Arabia: A prospective cohort study

Iatrogenic injury of posterolateral structures during femoral tunneling in anterior cruciate ligament reconstruction: A cadaveric study

Non-necrotizing and necrotizing soft tissue infections in South America: A retrospective cohort study

Perception and experience of academic Jordanian ophthalmologists with E-Learning for undergraduate course during the COVID-19 pandemic

 

International Journal of Pediatric Otorhinolaryngology

Volume 138

Interrupted cochlear implant habilitation due to COVID-19 pandemic-ways and means to overcome this

ENT management of children with adenotonsillar disease during COVID-19 pandemic. Ready to start again?

Laryngeal granular cell tumors in children: A literature review

Speech-language disorders in children with congenital Zika virus syndrome: A systematic review

 

Journal of Pediatric Surgery

Volume 55, Issue 10

Update on pediatric rhabdomyosarcoma: A report from the APSA Cancer Committee

Sedated ultrasound guided saline reduction (SUR) of ileocolic intussusception: 20 year experience

Sacrococcygeal teratoma with intraspinal extension: A case series and review of literature

Lymph node yield in pediatric, adolescent and young adult Renal Cell Carcinoma – How many are enough?

 

Lancet Infectious Diseases

Volume 20, Issue 11

The intersection of COVID-19 and mental health

COVID-19: from rapid genome sequencing to fast decisions

Should olanexidine be used routinely for surgical skin antisepsis?

The potential for improved protection against pertussis

Emerging macrolide resistance in Mycoplasma genitalium

Evaluating case definitions for Ebola virus disease

Access Latest Clinical Overviews:

Dizziness and giddiness – Dizziness describes any of various symptoms experienced by patients, including giddiness, lightheadedness, spinning sensation, or feeling faint – Read More..

Knee pain (nontraumatic) – Perception of pain in and around the knee may be caused by intrinsic conditions involving supporting structures of the knee (eg, joints, bones, muscles, ligaments, tendons, bursae) or referred from elsewhere (eg, hip, lumbar spine); most knee pain is caused by structures supporting the knee joint. Read More..

Nephritic syndrome – Nephritic syndrome is a clinical manifestation of glomerulonephritis, characterized by hematuria, proteinuria, impaired renal function, hypertension, and edema. Read More..

Weakness- Neuromuscular weakness is a common complaint that requires distinction from fatigue, asthenia, and psychogenic disease. Read More..

 

Updated Clinical Overviews – Selected Topics

Chronic kidney disease – Chronic kidney disease is the decline in function of the kidney characterized by at least 3 months of reduced GFR (less than 60 mL/minute/1.73 m²) or at least 3 months of structural or functional kidney damage. Read More..

Colorectal cancer – Colorectal cancer is a malignant neoplasm of the colon or rectum, most commonly adenocarcinoma; clinical presentation ranges from asymptomatic to imminently life-threatening (eg, perforation, obstruction). Read More..

Coronavirus: novel coronavirus (COVID-19) infection – COVID-19 (coronavirus disease 2019) is a respiratory tract infection due to a novel coronavirus, SARS-CoV-2; global pandemic is ongoing. Read More..

Generalized anxiety disorder – Generalized anxiety disorder is a mental disorder characterized by continuous and uncontrolled worrying without a significant cause. Read More..

Major depressive disorder – Major depressive disorder is a chronic and relapsing disease, characterized by a pervasive sad mood and the loss of pleasure in most activities (anhedonia) Read More..

COVID-19 PRACTICE UPDATES – 23rd Feb 2021

 The recent Oxford study on optimum prime-boost interval is very important from a clinical and public health policy perspective. Also the interim results of the Sputnik V Phase 3 trials (although not yet approved for emergency use in India) will be of clinical interest. Finally, a study to identify association between COVID-19 and major NCD risk factors, NCDs, healthcare related and social variables in India. Please find some related direct links.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose.…In the participants who received two standard doses, after the second dose, efficacy was higher in those with a longer prime-boost interval (vaccine efficacy 81·3% [95% CI 60·3–91·2] at ≥12 weeks) than in those with a short interval (vaccine efficacy 55·1% [33·0–69·9] at <6 weeks). These observations are supported by immunogenicity data that showed binding antibody responses more than two-fold higher after an interval of 12 or more weeks compared with an interval of less than 6 weeks in those who were aged 18–55 years (GMR 2·32 [2·01–2·68]).

 

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

This interim analysis of the phase 3 trial of Gam-COVID-Vac (Sputnik V) showed 91·6% efficacy against COVID-19 and was well tolerated in a large cohort.

Between Sept 7 and Nov 24, 2020, 21 977 adults were randomly assigned to the vaccine group (n=16 501) or the placebo group (n=5476). 19 866 received two doses of vaccine or placebo and were included in the primary outcome analysis. From 21 days after the first dose of vaccine (the day of dose 2), 16 (0·1%) of 14 964 participants in the vaccine group and 62 (1·3%) of 4902 in the placebo group were confirmed to have COVID-19; vaccine efficacy was 91·6% (95% CI 85·6–95·2). Most reported adverse events were grade 1 (7485 [94·0%] of 7966 total events). 45 (0·3%) of 16 427 participants in the vaccine group and 23 (0·4%) of 5435 participants in the placebo group had serious adverse events; none were considered associated with vaccination, with confirmation from the independent data monitoring committee. Four deaths were reported during the study (three [<0·1%] of 16 427 participants in the vaccine group and one [<0·1%] of 5435 participants in the placebo group), none of which were considered related to the vaccine.

Macrolevel association of COVID-19 with non-communicable disease risk factors in India

COVID-19 disease burden and mortality in India is ecologically associated with greater state-level burden of NCDs and risk factors, especially obesity and diabetes.

There is significant positive correlation (Pearson r) of state-level COVID-19 cases and deaths per million, respectively, with NCD risk factors- obesity (0.64, 0.52), hypertension (0.28, 0.16), diabetes (0.66, 0.46), NCD epidemiological transition index (0.58, 0.54) and ischemic heart disease mortality (0.22, 0.33). Correlation is also observed with indices of healthcare access and quality (0.71, 0.61), urbanization (0.75, 0.73) and human (0.61, 0.56) and sociodemographic (0.70, 0.69) development. Multivariate adjusted analyses shows strong correlation of COVID-19 burden and deaths with NCD risk factors (r 2 = 0.51, 0.43), NCDs (r 2 = 0.32, 0.16) and healthcare (r 2 = 0.52, 0.38).

Another Challenge on the rise!! Find latest articles related to Mucormycosis on ClinicalKey

Web Article

Mucormycosis(previously called zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. These molds live throughout the environment. Mucormycosis mainly affects people who have health problems or take medicines that lower the body’s ability to fight germsand sickness. It most commonly affects the sinuses or the lungs after inhaling fungal spores from the air. It can also occur on the skin after a cut, burn, or other type of skin injury.

Access Latest Articles:

  • Mucormycosisin COVID-19: A systematic review of cases reported worldwide and in IndiaDiabetes & Metabolic Syndrome: Clinical Research & Reviews https://bit.ly/3i1E87h
  • Mucormycosis-a serious threat in the COVID-19 pandemic?Journal of Infection https://bit.ly/3hPe2E4
  • Mucormycosis with orbital compartment syndrome in a patient with COVID-19American Journal of Emergency Medicine https://bit.ly/3hPe3I8
  • Recent Trends in the Epidemiology of Fungal InfectionsInfectious Disease Clinics of North America https://bit.ly/3fgsOC4
  • Sino-orbital mucormycosis in a COVID-19 patient: A case reportInternational Journal of Surgery Case Reports https://bit.ly/3ugc6qI
  • Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU https://bit.ly/3yxVDBQ
  • Infection prevention practices and the use of medical tapes AJIC: American Journal of Infection Control https://bit.ly/3uf9dqn